Who was studied, and how
Four numbers in the abstract
Where each one falls
Only randomized results vote
Where it lands on the map
What it changes
379people with kidney disease, in this paper
The trial randomly assignedassigned by chance
metformin 500 mg twice daily
placebo twice daily
No clear effect on contrast-induced acute kidney injury−4%
randomisedthe abstract, start to end
… not associated with CI-AKI (odds ratio: 0.96, 95%CI 0.52-1.75, P=0.88).
… (OR: 1.01 per 10 ml increase, 95%CI 0.98-1.03, P = 0.60).Table 3Predictors …
… predictor of CI-AKI (odds ratio (OR): 3.30, 95%CI 1.51-7.23, P < 0.01), as …
… (OR: 1.01 per 10 ml increase, 95%CI 0.98-1.03, P = 0.60).
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Contrast-induced acute kidney injury (CI-AKI)metformin 500 mg twice daily vs placebo twice daily
OR 0.960.52–1.75
Adverse events & safety
−1.03
Adverse events & safety
OR 3.301.51–7.23
Cardiovascular events
−1.03
MetforminAntihypertensivesCardiovascular eventsKidney outcomesAdverse events & safety
Metformin × kidney outcomeshelps?no deciding trial
unlikelylikely
0.25only evidence
1 / 6